← All trials
NCT00257790
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2001
- Primary completion
- —
- Completion date
- Mar 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 210
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Osaka UniversityLead sponsor
- The National Institute of Health, OsloCollaborator
- Sykehuset BuskerudCollaborator
- Sentralsjukehuset i HedemarkCollaborator
- University of StavangerCollaborator
- Osaka UniversityOverall official - principal investigator
- Sorlandet Hospital HFCollaborator
- Sykehuset Innlandet HFCollaborator
- The Hospital of VestfoldCollaborator
- University of OsloCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.